Literature DB >> 31301336

Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?

Niki Katsiki1, Nikolaos Perakakis1, Christos Mantzoros2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31301336     DOI： 10.1016/j.metabol.2019.07.009

Source DB:  PubMed          Journal:  Metabolism        ISSN： 0026-0495            Impact factor:   8.694


× No keyword cloud information.
  8 in total

1.  ZG02 Improved Hepatic Glucose Metabolism and Insulin Sensitivity via Activation of AMPK/Sirt1 Signaling Pathways in a High-fat Diet/Streptozotocin-induced Type 2 Diabetes Model.

Authors:  Yi Zhang; Bo Zhou; Min Wen; Mi Hu; Jin-Gang Peng; Ying Wang; Lin-Lin Fan; Lei Tang
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-12       Impact factor: 3.168

Review 2.  Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?

Authors:  Niki Katsiki; Ele Ferrannini
Journal:  J Diabetes Complications       Date:  2020-08-26       Impact factor: 2.852

Review 3.  SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews.

Authors:  Shih-Chieh Shao; Liang-Tseng Kuo; Rong-Nan Chien; Ming-Jui Hung; Edward Chia-Cheng Lai
Journal:  BMJ Open Diabetes Res Care       Date:  2020-12

4.  Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis.

Authors:  Narjes Nasiri-Ansari; Chrysa Nikolopoulou; Katerina Papoutsi; Ioannis Kyrou; Christos S Mantzoros; Georgios Kyriakopoulos; Antonios Chatzigeorgiou; Vassiliki Kalotychou; Manpal S Randeva; Kamaljit Chatha; Konstantinos Kontzoglou; Gregory Kaltsas; Athanasios G Papavassiliou; Harpal S Randeva; Eva Kassi
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

5.  Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro.

Authors:  Ting Li; Ting Fang; Linxin Xu; Xiangyang Liu; Xiaoyu Li; Mei Xue; Xiaochen Yu; Bei Sun; Liming Chen
Journal:  Front Pharmacol       Date:  2021-01-20       Impact factor: 5.810

Review 6.  Treatments for NAFLD: State of Art.

Authors:  Alessandro Mantovani; Andrea Dalbeni
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

7.  Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.

Authors:  Nikolaos Perakakis; Pavlina Chrysafi; Michael Feigh; Sanne Skovgard Veidal; Christos S Mantzoros
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

8.  Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors.

Authors:  Jake P Mann; Paul Carter; Matthew J Armstrong; Hesham K Abdelaziz; Hardeep Uppal; Billal Patel; Suresh Chandran; Ranjit More; Philip N Newsome; Rahul Potluri
Journal:  PLoS One       Date:  2020-10-27       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.